Time to reappraise the therapeutic place of celecoxib.
作者信息
Beales Ian L P
机构信息
Department of Gastroenterology, Norfolk and Norwich University Hospital, Norwich, NR4 7UY, UK.
出版信息
Ther Adv Chronic Dis. 2018 May;9(5):107-110. doi: 10.1177/2040622317749394. Epub 2018 Jan 3.
Abstract
摘要
相似文献
1
Time to reappraise the therapeutic place of celecoxib.是时候重新评估塞来昔布的治疗地位了。
Ther Adv Chronic Dis. 2018 May;9(5):107-110. doi: 10.1177/2040622317749394. Epub 2018 Jan 3.
2
Effects of Therapeutic Doses of Celecoxib on Several Physiological Parameters of Cultured Human Osteoblasts.塞来昔布治疗剂量对培养的人成骨细胞几种生理参数的影响。
Int J Med Sci. 2019 Sep 20;16(11):1466-1472. doi: 10.7150/ijms.37857. eCollection 2019.
3
Three levels face centered central composite design of colon targeted micro-particulates system of celecoxib: screening of formulations variables and in vivo studies.塞来昔布结肠靶向微颗粒系统的三水平面心中央复合设计：制剂变量筛选及体内研究
Curr Drug Deliv. 2014;11(5):621-35. doi: 10.2174/1567201811666140519161628.
4
Fixed-Dose Combination Amlodipine/Celecoxib (Consensi) for Hypertension and Osteoarthritis.固定剂量复方氨氯地平/塞来昔布（Consensi）治疗高血压和骨关节炎。
Am J Med. 2019 Feb;132(2):172-174. doi: 10.1016/j.amjmed.2018.08.027. Epub 2018 Sep 18.
5
Effects of dexamethasone or celecoxib on biliary toxicity after hepatic arterial infusion of 5-fluorodeoxyuridine in a canine model.
Cancer Res. 2004 Jan 1;64(1):311-5. doi: 10.1158/0008-5472.can-03-2588.
6
Economic outcomes for celecoxib: a systematic review of pharmacoeconomic studies.塞来昔布的经济学结局：药物经济学研究的系统评价。
Expert Rev Pharmacoecon Outcomes Res. 2012 Aug;12(4):505-23. doi: 10.1586/erp.12.36.
7
Effect of celecoxib, a selective cyclooxygenase-2 inhibitor on carbon tetrachloride intoxication in rats.塞来昔布（一种选择性环氧化酶-2 抑制剂）对大鼠四氯化碳中毒的影响。
Biol Pharm Bull. 2010;33(4):707-9. doi: 10.1248/bpb.33.707.
8
Use of celecoxib immediately post marketing in Canada: acute or chronic pain?塞来昔布在加拿大上市后立即使用：用于急性疼痛还是慢性疼痛？
Can J Clin Pharmacol. 2007 Winter;14(1):e70-80. Epub 2007 Mar 2.
9
Clinical therapeutic effect and safety of celecoxib in treating knee osteoarthritis.塞来昔布治疗膝骨关节炎的临床疗效及安全性
Pak J Pharm Sci. 2018 Jul;31(4(Special)):1629-1632.
10
Celecoxib: a review of its use in osteoarthritis, rheumatoid arthritis and acute pain.塞来昔布：对其在骨关节炎、类风湿关节炎及急性疼痛治疗中应用的综述。
Drugs. 2000 Apr;59(4):957-80. doi: 10.2165/00003495-200059040-00017.
引用本文的文献
1
Current Evidence on Celecoxib Safety in the Management of Chronic Musculoskeletal Conditions: An Umbrella Review.塞来昔布治疗慢性肌肉骨骼疾病安全性的现有证据：一项系统综述。
Drugs. 2025 Sep 5. doi: 10.1007/s40265-025-02234-5.
2
Selenocoxib-3, a novel anti-inflammatory therapeutic effectively resolves colitis.塞来昔布-3，一种新型抗炎疗法，可有效缓解结肠炎。
Mol Cell Biochem. 2023 Mar;478(3):621-636. doi: 10.1007/s11010-022-04532-y. Epub 2022 Aug 24.
3
Efficacy of an opioid-sparing analgesic protocol in pain control after less invasive cranial neurosurgery.一种阿片类药物节约型镇痛方案在微创颅脑神经外科手术后疼痛控制中的疗效。
Pain Rep. 2021 Aug 4;6(3):e948. doi: 10.1097/PR9.0000000000000948. eCollection 2021 Sep-Oct.
本文引用的文献
1
Risk of acute myocardial infarction with NSAIDs in real world use: bayesian meta-analysis of individual patient data.非甾体抗炎药在实际应用中导致急性心肌梗死的风险：个体患者数据的贝叶斯荟萃分析
BMJ. 2017 May 9;357:j1909. doi: 10.1136/bmj.j1909.
2
Gastrointestinal safety of celecoxib versus naproxen in patients with cardiothrombotic diseases and arthritis after upper gastrointestinal bleeding (CONCERN): an industry-independent, double-blind, double-dummy, randomised trial.在上消化道出血后患有心血管血栓疾病和关节炎的患者中，塞来昔布与萘普生的胃肠道安全性 (CONCERN)：一项产业独立、双盲、双模拟、随机试验。
Lancet. 2017 Jun 17;389(10087):2375-2382. doi: 10.1016/S0140-6736(17)30981-9. Epub 2017 Apr 11.
3
Non-steroidal anti-inflammatory drug-induced cardiovascular adverse events: a meta-analysis.非甾体抗炎药引起的心血管不良事件：一项荟萃分析。
J Clin Pharm Ther. 2017 Feb;42(1):27-38. doi: 10.1111/jcpt.12484. Epub 2016 Dec 26.
4
Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis.塞来昔布、萘普生或布洛芬治疗关节炎的心血管安全性。
N Engl J Med. 2016 Dec 29;375(26):2519-29. doi: 10.1056/NEJMoa1611593. Epub 2016 Nov 13.
5
Prevention of upper gastrointestinal haemorrhage: current controversies and clinical guidance.预防上消化道出血：当前的争议和临床指导。
Ther Adv Chronic Dis. 2013 Sep;4(5):206-22. doi: 10.1177/2040622313492188.
6
Cyclooxygenase-1, not cyclooxygenase-2, is responsible for physiological production of prostacyclin in the cardiovascular system.环氧化酶-1（COX-1）而非环氧化酶-2（COX-2）负责心血管系统中前列腺素 I2（prostacyclin）的生理性生成。
Proc Natl Acad Sci U S A. 2012 Oct 23;109(43):17597-602. doi: 10.1073/pnas.1209192109. Epub 2012 Oct 8.
7
Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial.塞来昔布与奥美拉唑和双氯芬酸治疗骨关节炎和类风湿关节炎患者（CONDOR）：一项随机试验。
Lancet. 2010 Jul 17;376(9736):173-9. doi: 10.1016/S0140-6736(10)60673-3. Epub 2010 Jun 16.
8
Are COX-2 inhibitors preferable to non-selective non-steroidal anti-inflammatory drugs in patients with risk of cardiovascular events taking low-dose aspirin?对于有心血管事件风险且正在服用低剂量阿司匹林的患者，COX-2抑制剂是否比非选择性非甾体抗炎药更可取？
Lancet. 2007 Dec 22;370(9605):2138-51. doi: 10.1016/S0140-6736(07)61909-6.
9
Combination of a cyclo-oxygenase-2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a double-blind, randomised trial.环氧化酶-2抑制剂与质子泵抑制剂联合用于预防极高风险患者复发性溃疡出血：一项双盲随机试验
Lancet. 2007 May 12;369(9573):1621-6. doi: 10.1016/S0140-6736(07)60749-1.
10
Cyclooxygenase-2 selectivity of non-steroidal anti-inflammatory drugs and the risk of myocardial infarction and cerebrovascular accident.非甾体抗炎药的环氧化酶-2选择性与心肌梗死和脑血管意外风险
Aliment Pharmacol Ther. 2007 Apr 15;25(8):913-24. doi: 10.1111/j.1365-2036.2007.03292.x.
Zotero 插件